Core Insights - NeoGenomics, Inc. announced the presentation of data from its RaDaR 1.0 assay for detecting molecular residual disease (MRD) at the 2025 San Antonio Breast Cancer Symposium (SABCS) [1][2] - The studies presented will focus on the role of circulating tumor DNA (ctDNA) in early breast cancer research and recurrence monitoring, highlighting its potential to provide actionable insights for patient care [2][4] Company Overview - NeoGenomics is a leading cancer diagnostics company specializing in cancer genetics testing and information services, offering a comprehensive oncology-focused testing menu [4] - The company operates CAP-accredited and CLIA-certified laboratories across the US and in the UK, providing full-service sample processing and analysis [4] Study Presentations - The findings from the CLEVER trial indicate that RaDaR-detected ctDNA can precede clinical recurrence in high-risk breast cancer patients, with positive ctDNA often detected months before relapse [5] - The SURVIVE Phase III trial aims to evaluate whether liquid biopsy-guided follow-up using the RaDaR assay can enable earlier detection of recurrence and improve overall survival [5] - The SURVIVE HERoes trial focuses on treating patients at the point of molecular relapse, assessing if early intervention can enhance long-term outcomes in HER2-positive or HER2-low early breast cancer [5]